Saturday, 31 October 2026European Markets

OREGE Stock Bullish Momentum With A 21.96% Rise Today

Loading stream...

(vianews) - the market ended the session with orege (orege.pa) rising 21.96% to €0.62 on tuesday while cac 40 dropped 1.1% to €7,267.70.

orege's last close was €0.51, 37.8% below its 52-week high of €0.82.

about orege

orege société anonyme designs, develops, operates, manufactures, and markets municipal and industrial sludge, and effluents treatment solutions in france, the united states, japan, germany, and the united kingdom. the company offers slg solution for conditioning, treating, and recovering municipal and industrial sludge; slg-f, a combination of slg conditioning solution; and flosep for sludge separation and thickening tool. it also provides after-sales, installation and commissioning, operator training, warranty extensions, maintenance, and process line optimization services. the company was incorporated in 2005 and is headquartered in voisins-le-bretonneux, france. orege société anonyme is a subsidiary of eren groupe sa.

earnings per share

as for profitability, orege has a trailing twelve months eps of €-0.12.

volume

today's last reported volume for orege is 202934 which is 12.37% below its average volume of 231584.

moving average

orege's worth is way above its 50-day moving average of €0.44 and way higher than its 200-day moving average of €0.43.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, orege's stock is considered to be overbought (>=80).

yearly top and bottom value

orege's stock is valued at €0.62 at 22:32 est, way below its 52-week high of €0.82 and way higher than its 52-week low of €0.18.

more news about orege (orege.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com